Mathias W.

Investigator engages in trials targeting malignant blood disorders such as Acute Lymphoblastic Leukemia and Multiple Myeloma.

• Acute Lymphoblastic Leukemia (ALL)
• Acute Myeloid Leukemia (AML)
• Multiple Myeloma with prior therapy exposure
• Relapsed or refractory B‑cell lymphomas

Efforts aim to improve survival through novel immunotherapeutic approaches.

Investigator participates in studies of diverse solid cancers, including thoracic, gastrointestinal and cutaneous malignancies such as Non‑Small Cell Lung Cancer and Melanoma.

• Non‑Small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)
• Advanced Melanoma resistant to checkpoint inhibition
• Metastatic colorectal and pancreatic adenocarcinomas
• HER2‑positive and HER2‑negative breast cancers

Focus is on targeted and immune‑based regimens for advanced disease.

Investigator explores therapies for protein‑misfolding disorders, notably AL Amyloidosis, ATTR‑CM and related cardiac manifestations.

• AL Amyloidosis with cardiac involvement
• Transthyretin Amyloid Cardiomyopathy (ATTR‑CM)
• Heart failure with reduced ejection fraction
• Cardiomyopathy due to genetic mutations

Therapeutic goals include stabilizing amyloid fibrils and improving cardiac function.

Investigator contributes to studies on immune complications after hematopoietic stem cell transplantation, focusing on Acute Graft‑Versus‑Host Disease and chronic forms.

• Acute Graft‑Versus‑Host Disease of the gastrointestinal tract
• Chronic graft‑versus‑host disease (cGVHD)
• Stem cell transplant‑associated thrombotic microangiopathy
• Infection prophylaxis in post‑transplant patients

Research aims to mitigate immune-mediated injury while preserving graft efficacy.